YouTube video by Stevie Wonder - Topic

YouTube video by Stevie Wonder - Topic

OmniAb CLO Berkman sold $10,663 of OABI stock on Apr 8, 2026, filed on Form 4 within the SEC's two-day rule; transaction is modest and likely low market impact.

OmniAb (NASDAQ: OABI) reported fourth-quarter and full-year 2025 results and provided 2026 guidance on March 4, 2026. Full-year 2025 revenue was $18.7M with a net loss of $64.8M and cash, equivalents and short-term investments of $54.0M at year-end.The company exited 2025 with 107 active partners, 407 active programs and launched OmniUltra. 2026 guidance is revenue of $25–30M, operating expenses of $80–85M, cash costs of $50–55M, and expected year-end cash of $30–35M.

A compilation of screaming animals

OmniAb (NASDAQ: OABI) announced a global collaboration and license agreement with Eli Lilly and Company for a new ion channel discovery program. The partnership will use OmniAb’s technology platform and ion channel discovery and screening expertise to support Lilly’s efforts to develop next-generation therapeutics.According to OmniAb, the company will receive an upfront payment and is eligible for up to $370 million in research, development and commercial milestone payments, plus tiered royalties on global net sales for any resulting products. The specific therapeutic target and modality for the ion channel program remain undisclosed.

OmniAb signs a global license deal with Eli Lilly focused on ion channel drug discovery, with an upfront payment, milestones, and tiered royalties.

OmniAb (NASDAQ: OABI) raised its full-year 2026 cash and cash equivalents guidance following recent technology licensing activity. The company now expects to end 2026 with $49 million to $53 million in cash and cash equivalents, compared with its prior range of $37 million to $41 million.Management attributed the improved outlook to recent business development and licensing activity and indicated that partnerships using OmniAb’s discovery research technologies are expanding in scope and depth. Leadership reiterated a focus on leveraging its technology suite and partner ecosystem to support growth and long-term value creation.

OmniAb had $52.0M in cash, 110 active partners and 425 active programs as of June 30; Investor Day is set for Oct. 6, 2026.

YouTube video by Stevie Wonder - Topic

VERAXA Biotech (NASDAQ: VRXA) announced that bispecific antibody-drug conjugate program VXA-222, originating from its May 2025 alliance with OmniAb (NASDAQ: OABI), has achieved a key technical milestone and is advancing into the next collaboration phase as OmniAb’s discovery work has concluded.VXA-222 is a bispecific ADC using an “AND-gate” design to target two antigens on solid tumors in a single molecule. VERAXA used OmniAb’s transgenic antibody discovery technologies, including OmniClic, to generate antibody leads and will now apply its proprietary linker and conjugation technology, and conduct in vitro and in vivo validation. VERAXA holds exclusive development and commercialization rights to products using OmniAb-derived antibodies, while OmniAb is entitled to a share of specified revenue from such products.

Thermo Fisher and Danaher alumnus Amechi Nwachuku becomes OmniAb EVP and COO, leading strategy, operations and commercialization of its xPloration platform.